What is the 13F Pro Quality Score for CTMX?

13F Pro ranks CytomX Therapeutics, Inc. (CTMX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CTMX's current score at https://13fpro.ai/research/CTMX (free sign-up required for the full ranking).

Which hedge funds own the most CTMX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CTMX include FMR, Kynam Capital Management,, BANK OF AMERICA /DE/. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CTMX as soon as new 13F filings post.

Where does 13F Pro source CTMX data?

All CytomX Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. CytomX Therapeutics, Inc. files with the SEC under CIK 1501989. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CTMX in?

CytomX Therapeutics, Inc. (CTMX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CTMX research updated on 13F Pro?

CTMX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CytomX Therapeutics, Inc.(CTMX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1501989 CTMX stock profile & AI dashboard →

13F Pro Quality Score

19.1/100

Rank #2,701 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

9.3/100

Profitability

18.6/100

Balance Sheet

22.7/100

Earnings Quality

30.0/100

Free Cash Flow

7.2/100

Institutional Flow

85.2/100

Revenue Scale

15.8/100

Dilution Risk

19.2/100

CTMX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CytomX Therapeutics, Inc. (CTMX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTMX at 19.1/100 on a 32-signal composite quality model, placing it at rank #2,701 of 2,879 stocks — the bottom half of the AI-ranked universe. CTMX scores in the top quartile across institutional flow (85.2). Areas of concern include free cash flow (7.2) and revenue growth (9.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CytomX Therapeutics, Inc. reports quarterly revenue of $10.3M, net income of $-18.2M, free cash flow of $-25.5M. Top institutional holders of CTMX by reported 13-F value include FMR, Kynam Capital Management,, BANK OF AMERICA /DE/, based on the most recent SEC filings. CTMX trades on the Nasdaq exchange and files with the SEC under CIK 1501989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CytomX Therapeutics, Inc. directly from SEC EDGAR. CytomX Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 61 since 2021, currently 19.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about CytomX Therapeutics, Inc.

Quirks, history, and lore behind CTMX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the heart of biotech country.
2
The Numbers
With no approved products and a market cap well under $500 million, its revenue comes almost entirely from research collaborations — not sales.
3
The History
Founded in the mid-2010s, it was spun out of early-stage oncology research and quickly partnered with some of the biggest names in cancer drug development.
4
The Secret
Its core idea: build antibodies that stay switched off in healthy tissue but automatically activate inside tumors, shrinking side effects that plague conventional cancer drugs.
5
The Lore
The technology is called a Probody — a masked antibody that only unmasks in the tumor microenvironment, and it's the kind of concept that makes oncologists and investors alike sit up straight.
6
The Giveaway
Its ticker is a near-anagram of its mission: smarter cancer therapeutics built on a proprietary CX platform of conditionally activated biologics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.3M

Net Income

Q1 2026

$-18.2M

Free Cash Flow

Q1 2026

$-25.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+90.4% YoY

$101.2MFY 2023

FY20 $100.4MFY21 $37.3MFY22 $53.2MFY23 $101.2M

Net Income

+99.4% YoY

$-569.0KFY 2023

FY20 $-32.9MFY21 $-115.9MFY22 $-99.3MFY23 $-569.0K

Operating Income

+93.6% YoY

$-6.5MFY 2023

FY20 $-80.5MFY21 $-116.0MFY22 $-101.3MFY23 $-6.5M

Total Assets

-22.7% YoY

$201.8MFY 2023

FY20 $358.7MFY21 $339.4MFY22 $260.9MFY23 $201.8M

Op. Cash Flow

+49.4% YoY

$-56.0MFY 2023

FY20 $5.3MFY21 $-119.0MFY22 $-110.8MFY23 $-56.0M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$101.2M +90.4%	$53.2M +42.5%	$37.3M -62.8%	$100.4M +68.7%	$59.5M -16.9%	$71.6M
Net Income	$-569.0K +99.4%	$-99.3M +14.3%	$-115.9M -252.3%	$-32.9M +61.1%	$-84.6M -96.3%	$-43.1M
Operating Income	$-6.5M +93.6%	$-101.3M +12.7%	$-116.0M -44.1%	$-80.5M -3.4%	$-77.9M -68.3%	$-46.3M
Total Assets	$201.8M -22.7%	$260.9M -23.1%	$339.4M -5.4%	$358.7M -21.5%	$457.1M +15.0%	$397.6M
Operating Cash Flow	$-56.0M +49.4%	$-110.8M +6.9%	$-119.0M -2363.4%	$5.3M +107.0%	$-75.5M -144.3%	$170.4M

AI Insight: CTMX Financial Trends

Revenue collapsed from $51M in Q1 2025 to $1M in Q4 2025 before partially recovering, while equity surged to $320M in Q1 2026.

• Revenue declined dramatically from $51M peak in Q1 2025 to $1M trough in Q4 2025.

• Operating income turned negative after Q1 2025, falling to -$28M in Q4 2025.

• Equity jumped from $25M in Q1 2025 to $320M in Q1 2026, likely from financing.

• Operating cash flow remained consistently negative throughout the period, ranging from -$16M to -$26M.

⚠ Revenue recovery sustainability after bottoming at $1M in Q4 2025 with only modest rebound to $10M.

⚠ Persistent negative operating cash flow despite equity infusion suggests ongoing operational challenges.

AI Insight: CTMX Ratio Trends

CytomX margins collapsed from 44% profitability in Q1 2025 to -192% operating margin in Q1 2026, marking a dramatic reversal.

• Operating margin plunged from 44.4% in Q1 2025 to -191.8% in Q1 2026, erasing prior profitability gains.

• Net profit margin deteriorated from 46.2% in Q1 2025 to -177.9% in Q1 2026, reflecting severe operational challenges.

• ROA crashed from 95.5% in Q1 2025 to -20.3% in Q1 2026, indicating poor asset utilization.

• ROIC turned deeply negative at -24.6% in Q1 2026 after being positive earlier in the period.

⚠ Profitability peaked in Q4 2024 and Q1 2025 before steep deterioration — monitor sustainability of business model.

⚠ Missing operating data in Q3-Q4 2025 creates visibility gaps during the transition to losses.

Get alerted when CTMX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CytomX Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CTMX

FMR LLC
$150.2M31,955,637 sh
Kynam Capital Management, LP
$70.6M15,013,093 sh
BANK OF AMERICA CORP /DE/
$48.0M10,202,785 sh
PERCEPTIVE ADVISORS LLC
$47.5M10,098,824 sh
VR Adviser, LLC
$46.9M9,982,124 sh
VANGUARD CAPITAL MANAGEMENT LLC
$41.0M8,733,118 sh
Point72 Asset Management, L.P.
$37.0M7,875,390 sh
STATE STREET CORP
$26.6M5,663,408 sh
CITADEL ADVISORS LLC
$25.4M5,406,193 sh
BlackRock, Inc.
$24.6M5,228,280 sh

Fund	Value	Shares
FMR LLC	$150.2M	31,955,637
Kynam Capital Management, LP	$70.6M	15,013,093
BANK OF AMERICA CORP /DE/	$48.0M	10,202,785
PERCEPTIVE ADVISORS LLC	$47.5M	10,098,824
VR Adviser, LLC	$46.9M	9,982,124
VANGUARD CAPITAL MANAGEMENT LLC	$41.0M	8,733,118
Point72 Asset Management, L.P.	$37.0M	7,875,390
STATE STREET CORP	$26.6M	5,663,408
CITADEL ADVISORS LLC	$25.4M	5,406,193
BlackRock, Inc.	$24.6M	5,228,280

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CTMX on your watchlist

Track score changes the day CytomX Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CTMX a good stock to buy?

13F Pro's AI-powered analysis of CytomX Therapeutics, Inc. (CTMX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTMX are available on the CTMX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CTMX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTMX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CytomX Therapeutics, Inc.'s investment landscape.